# A Study of Anti-VEGF Monoclonal Antibody hPV19 in Patients With Solid Tumors

> **NCT03503604** · PHASE1 · UNKNOWN · sponsor: **SuZhou Stainwei Biotech Inc.** · enrollment: 18 (estimated)

## Conditions studied

- Solid Tumors

## Interventions

- **BIOLOGICAL:** hPV19 mAb
- **BIOLOGICAL:** hPV19 mAb
- **DRUG:** 5-Fluorouracil
- **DRUG:** Oxaliplatin
- **DRUG:** Leucovorin
- **DRUG:** Paclitaxel
- **DRUG:** Carboplatin
- **DRUG:** Gemcitabine
- **DRUG:** Carboplatin
- **DRUG:** Irinotecan

## Key facts

- **NCT ID:** NCT03503604
- **Lead sponsor:** SuZhou Stainwei Biotech Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-05-01
- **Primary completion:** 2019-01-01
- **Final completion:** 2019-03-01
- **Target enrollment:** 18 (ESTIMATED)
- **Last updated:** 2018-04-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03503604

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03503604, "A Study of Anti-VEGF Monoclonal Antibody hPV19 in Patients With Solid Tumors". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03503604. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*